Cyted Health: From fellow to funding for early cancer detection
Cambridge-based Cyted Health has secured $44 million in Series B funding, a major milestone that will accelerate its US expansion and strengthen its UK operations. At the centre of this success is EndoSign®, a swallowable capsule that collects oesophageal cells for lab analysis, providing a simple, patient-friendly alternative to invasive endoscopy.
This innovation tackles a pressing challenge: oesophageal cancer survival rates remain at just 20%, largely due to late diagnosis. By enabling fast, community-based testing, EndoSign® is helping the NHS and health systems worldwide detect disease earlier and save lives.
Catalysed by the NHS Innovation Accelerator
Cyted’s journey was fast-tracked when it joined the NHS Innovation Accelerator (NIA) in 2021.
“Since joining the NIA, we have significantly expanded our footprint within the NHS and built a robust portfolio of peer-reviewed publications and real-world data. Being part of the programme has given us visibility and credibility, strengthening confidence among clinicians and commissioners. This support helped us move from early pilots to widespread NHS use, ensuring our innovation delivers real impact for patients.”
Today, Cyted’s diagnostics platform is widely adopted across the NHS, with over 35,000 tests delivered to date – proof that the company’s technology has moved well beyond proof of concept.
Scaling success in the UK
The recent Series B fundraising round raised $44 million for Cyted and marks a defining moment for them as they continue to deepen their commitment to detecting oesophageal diseases earlier.
“Five years ago, we delivered our first clinical test in a real-world setting, and we could never have imagined what the following years would bring. Our platform is now widely used across the NHS, with unmatched patient acceptability and proven clinical impact. Every 15 minutes, a patient receives one of our minimally invasive EndoSign® tests.”
Cyted’s technology has also been included in clinical guidelines worldwide, underlining its role in shaping global best practice.
Looking ahead: Global expansion and new diagnostics
The new investment – led by EQT Life Sciences, alongside Advent Life Sciences, the British Business Bank, and others – will fund Cyted’s US commercial expansion and support its growing diagnostics portfolio. A partnership with HCA Healthcare adds further strategic momentum to their plans.
“Earlier this year, we launched the DETECT-ME clinical validation study across 18 sites to build an evidence base for EndoSign® in the US market. These results, alongside our new investment, will help bring our platform to patients in the US, where over 18,000 people are diagnosed with oesophageal cancer each year. We are also advancing new diagnostic tests for upper GI conditions like eosinophilic esophagitis, with a strong R&D pipeline for the coming years.”
Why it matters
Cyted Health’s journey shows how breakthrough innovation can be scaled nationally when the right support is in place. With the help of the NHS Innovation Accelerator, the company has moved from early pilots to widespread NHS adoption, delivering over 35,000 tests and embedding EndoSign® into routine care.
Now, backed by $44 million in new investment, Cyted is poised to expand into the US and advance a new pipeline of gastrointestinal diagnostics. From Cambridge labs to global healthcare systems, its progress highlights how innovation, when nurtured and scaled, can transform patient outcomes worldwide.
You can view the full news story on Cyted’s website.
